Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy

Trial Profile

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Lomitapide (Primary)
  • Indications Hyperlipoproteinaemia type II
  • Focus Registrational; Therapeutic Use
  • Sponsors Aegerion Pharmaceuticals
  • Most Recent Events

    • 21 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2016 According to Aegerion Pharmaceuticals media release, based upon the data of this trial, Japan's Ministry of Health, Labor & Welfare (MHLW) has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).
    • 11 Jan 2016 According to an Aegerion Pharmaceuticals media release, the company has submitted a New Drug Application to the Ministry of Health, Labour and Welfare (MHLW) for marketing approval of JUXTAPID for the treatment of homozygous familial hypercholesterolemia (HoFH) in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top